Lantern Pharma Inc (LTRN)

Etorro trading 970x250
Lantern Pharma Inc (LTRN) Logo

About Lantern Pharma Inc

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas. Address: 1920 McKinney Avenue, Dallas, TX, United States, 75201

Lantern Pharma Inc News and around…

Latest news about Lantern Pharma Inc (LTRN) common stock and company :

12 Health Care Stocks Moving In Monday's Pre-Market Session
24 Jan, 2022 FinancialContent

Gainers SAB Biotherapeutics (NASDAQ:SABS) stock moved upwards by 15.0% to $6.3 during Monday's pre-market session. ...

Lantern Pharma's LP-184 Receives Rare Pediatric, Orphan Drug Tags For Rare Form Of Cancer
24 Jan, 2022 FinancialContent

TheFDA has granted Rare Pediatric Disease and Orphan Drug DesignationstoLantern Pharma Inc's(NASDAQ: LTRN) ...

Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous System
24 Jan, 2022 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development today announced that the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation and Orphan Drug Designation for the company's drug candidate LP-184 for the treatment of pediatric patients with ATRT. LP-184 is being pursued as a potent

LTRN: Multiple Collaborations Illuminating Way Forward
20 Jan, 2022 Yahoo! Finance

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Since Our Last Update Lantern Pharma, Inc. (NASDAQ:LTRN) has promulgated several updates since our report on the company’s third quarter 2021 results. In its latest corporate presentation, Lantern also updated the number of datapoints that have been accumulated on its Response Algorithm for Drug Positioning & Rescue

Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors
18 Jan, 2022 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a collaboration and research agreement with The Danish Cancer Society Research Center (DCRC) to support clinical development of Lantern's acylfulvene class drug candidates, LP-100 and LP-184, as well as the development of improved diagnostic methods to i

Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute - Accelerating Path to First in Human Clinical Trials for Drug Candidates LP-184 & LP-284
12 Jan, 2022 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it has expanded its collaboration agreement with the Developmental Therapeutics Branch (DTB) of the National Cancer Institute (NCI) of the National Institutes of Health. The expansion of this collaboration comes after identifying several gene signatures

Lantern Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference
04 Jan, 2022 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Panna Sharma, Chief Executive Officer and President of Lantern Pharma, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022. The presentation will be conducted as a fireside chat hosted by H.C

Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting
14 Dec, 2021 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern Pharma presented positive data on the effectiveness of LP-284 in hematologic cancers at the 63rd American Society of Hematology (ASH) Annual Meeting, which was held in-person and virtually from December 11 – 14, 2021. This poster presentatio

Lantern Pharma Announces Share Repurchase Program
22 Nov, 2021 Yahoo! Finance

Lantern Pharma Inc. (NASDAQ: LTRN) ("Lantern" or the "Company"), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that its board of directors has authorized a share repurchase program to acquire up to $7 million of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated tran

Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90+ Companies
15 Nov, 2021 FinancialContent
Lantern Pharma to Host Virtual KOL Event on the Potential Treatment of Pancreatic Cancer with Drug Candidate LP-184 on November 18th, World Pancreatic Cancer Day
12 Nov, 2021 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it will host a virtual Key Opinion Leader (KOL) event regarding the potential treatment of pancreatic cancer utilizing Lantern Pharma's drug candidate LP-184, on World Pancreatic Cancer Day, Thursday, November 18th at 12:00 pm EST.

Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Glioblastoma Accepted for Presentation at the Society for Neuro-Oncology 2021 Annual Meeting
11 Nov, 2021 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern Pharma's abstract on the effectiveness of LP-184 in glioblastoma multiforme (GBM) regardless of MGMT status has been accepted as a virtual poster at the upcoming 26th Society for Neuro-Oncology (SNO) Annual Meeting, which is being held in pe

Lantern Pharma to Participate in Two Upcoming Investor Conferences
09 Nov, 2021 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that management will be participating in two upcoming investor conferences.

We Think Lantern Pharma (NASDAQ:LTRN) Can Afford To Drive Business Growth
08 Nov, 2021 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers Accepted for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting
04 Nov, 2021 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern Pharma's abstract on the effectiveness of LP-284 in hematologic cancers has been accepted as a poster at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting, which is being held in-person and virtually from December 11 – 14

LTRN: 3Q:21 Results
03 Nov, 2021 Yahoo! Finance

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Third Quarter 2021 Financial and Operational Results On November 1, 2021, Lantern Pharma, Inc. (NASDAQ:LTRN) announced third quarter 2021 financial and operational results, filed its form 10-Q with the SEC and hosted a video webcast to review the quarter’s accomplishments. Highlights year-to-date include: ➢ Launched ADC

Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights
01 Nov, 2021 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today provided a business update and reported financial results for the third quarter ended September 30, 2021.

Lantern Pharma's Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 10 Billion Datapoints - Significantly Enhancing Precision Medicine Capabilities & Expanding Potential for Biopharma Collaborations and Partnerships
01 Nov, 2021 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that its proprietary A.I. platform RADR® has exceeded 10.4 billion datapoints. RADR® is Lantern's proprietary integrated A.I. platform for large-scale biomarker and drug-tumor interaction data analytics that leverages machine-learning. RADR® is used to p

Earnings Scheduled For November 1, 2021
01 Nov, 2021 FinancialContent

Companies Reporting Before The Bell • ANI Pharmaceuticals (NASDAQ:ANIP) is expected to report earnings for its third ...

Code Ocean Selected by Lantern Pharma to Power A.I. and Computational Biology Research & Data-Driven Oncology Drug Development Collaborations
27 Oct, 2021 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a collaboration that will power A.I.-driven computational research for oncology-focused drug discovery and development with Code Ocean, the leading computational research environment for sharing scientific discoveries. By leveraging Code Ocean's Compute

Code Ocean Selected by Lantern Pharma to Power A.I. Focused Computational Research Environment for Oncology Drug Development
27 Oct, 2021 Yahoo! Finance

Code Ocean, the leading computational research environment for sharing scientific discoveries, today announced a collaboration that will power AI-driven computational research for oncology-focused drug discovery with Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development. By leveraging Code Ocean's Compute Capsule® technolog

Lantern Pharma to Host Third Quarter 2021 Operating & Financial Results Conference Call on Monday, November 1, 2021 at 4:30 p.m. ET
25 Oct, 2021 Yahoo! Finance

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced today that it will host a conference call on Monday, November 1, 2021 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

12 Health Care Stocks Moving In Friday's Intraday Session
08 Oct, 2021 FinancialContent

Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 ...

12 Health Care Stocks Moving In Thursday's Intraday Session
07 Oct, 2021 FinancialContent

Gainers Nanobiotix (NASDAQ:NBTX) shares rose 13.2% to $12.0 during Thursday's regular session. The market value of ...

Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
07 Oct, 2021 FinancialContent

Upgrades For State Street Corporation (NYSE:STT), Wolfe Research upgraded the previous rating of Peer Perform to ...

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

36 of the Best Ideas Companies to Present at the Fall Harvest - Best Ideas from the Buy-Side Virtual Investor Conference on October 5th - 8th, 2021
04 Oct, 2021 Yahoo! Finance

RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5th \- 8th, 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The Fall Harvest - Best Ideas from the Buy Side: VIRTUAL begins on Tuesday, October 5th, 2021, with company presentations beginning at 8:30 am Eastern Time.

Lantern Pharma to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Wednesday, October 6, 2021
30 Sep, 2021 FinancialContent
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
29 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

Lantern Pharma Inc (LTRN) is a NASDAQ Common Stock listed in , ,

970x250